TTP-273 is under clinical development by VTv Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TTP-273’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTP-273 overview
TTP-273 is under development for the treatment of type 2 diabetes and impaired glucose tolerance (cystic fibrosis related diabetes). It is administered as tablet through oral route. The drug candidate acts by targeting non-peptide GLP1 receptor. The development of the drug candidate is based on TTP translational technology.
It was also under development for type 2 diabetes.
VTv Therapeutics overview
vTv Therapeutics (vTv) is a pharmaceutical company that discovers, develops and commercializes human therapeutics. The company’s pipeline product portfolio includes small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer. Its products include azeliragon, TTP399, TTP273, HPP593 and HPP737. vTv utilizes TTP translational technology to deliver clinical drug candidates against biological targets including protein-protein interactions, receptor modulators and enzyme inhibitors. The company collaborates with other pharmaceutical companies to discover and develop small molecule therapeutics for the treatment of major diseases. vTv is headquartered in High Point, North Carolina, the US.
For a complete picture of TTP-273’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
